Testing ALE1 for hypophosphatasia in healthy people and patients
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a new medicine called ALE1 for hypophosphatasia (HPP), a rare bone condition. It first checks safety in healthy volunteers, then tests if the medicine helps people with HPP.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be generally healthy for the first part of the study.
- If you have HPP, you need a confirmed change in the ALPL gene.
- You cannot have taken other treatments for HPP or osteoporosis before.
- You cannot have a recent fracture (within the last 12 weeks).
- You cannot have thyroid or parathyroid problems (unless related to HPP).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a registry that collects information about people with hypophosphatasia to help researchers understand the condition better. It may help future studies, but it’s not a treatment trial.
This study aims to find better ways to diagnose hypophosphatasia (HPP) in adults who see a rheumatologist. If your doctor suspects HPP and you have a low ALP blood test, you may be able to help researchers develop a screening tool.
This study looks at how changes in the ALPL gene affect the natural course of hypophosphatasia (HPP). It aims to learn more about the condition in people who have not received enzyme replacement therapy.
This study follows people who already have hypophosphatasia (HPP) to better understand how the condition changes over time. It may help doctors recognize patterns and improve care, even if you are not receiving a new treatment.
This is a long-term observational study (not a drug trial) that follows adults with signs of hypophosphatasia, a condition linked to very low alkaline phosphatase levels and sometimes a gene change. It aims to better understand the condition over time and how symptoms look and progress.
This study follows children with hypophosphatasia (HPP) to better understand how they do while receiving asfotase alfa. It may help improve care for families living with pediatric-onset HPP.
Hear when a new Hypophosphatasia (HPP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.